Drug data last refreshed 9h ago · AI intelligence enriched 6d ago
COSOPT PF is a fixed-dose combination ophthalmic solution containing dorzolamide (carbonic anhydrase inhibitor) and timolol (non-selective beta-blocker) for the treatment of elevated intraocular pressure in glaucoma and ocular hypertension. The preservative-free formulation reduces ocular irritation while maintaining dual mechanism efficacy through aqueous humor suppression.
Product is at peak maturity with modest Part D spending (~$893K in 2023); team focus likely on defending share against generic and competitive pressures rather than expansion.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on COSOPT PF offers stability and expertise in ophthalmology/glaucoma market but limited growth trajectory; roles focus on defensive marketing, generic competition mitigation, and maintaining clinical relationships with prescribers. Career advancement depends on successful share defense and leveraging the preservative-free differentiation.
Worked on COSOPT PF at Thea Pharma? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/mo